What changed: Hodgkin lymphoma
Every dated change on the records linked to Hodgkin lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
March 2026 · 1
2026 · 8
- 2026ApprovalNivolumabNivolumab approved in US
Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
- 2026GuidelineHodgkin lymphomaGuideline NCCN 2026: Advanced stage (III-IV), age ≤60
Nivolumab-AVD × 6 (S1826; approved March 2026, no routine radiotherapy) or BV-AVD × 6 with G-CSF (ECHELON-1); in Europe PET-guided BrECADD × 4-6 (HD21) or eBEACOPP; PET-adapted ABVD/AVD (RATHL) where novel agents unavailable. (NCCN Category 1 (nivolumab-AVD preferred; BV-AVD), ESMO-MCBS A (ECHELON-1))
- 2026GuidelineHodgkin lymphomaGuideline NCCN 2026: Early stage, unfavourable (I-II bulky or risk factors)
ABVD × 4 + ISRT 30 Gy, or escalated BEACOPP × 2 + ABVD × 2 + RT (HD14/HD17 PET-guided); nivolumab- or BV-containing regimens in trials. (NCCN Category 2A)
- 2026GuidelineHodgkin lymphomaGuideline NCCN 2026: First relapse, transplant-eligible
Salvage (ICE, DHAP, GVD, BV-nivolumab or pembrolizumab-GVD) → PET-negative → high-dose therapy and autologous transplant; brentuximab consolidation for high-risk (AETHERA); PD-1 maintenance in trials. (NCCN Category 1 (ASCT after chemosensitive salvage; BV consolidation for high risk))
- 2026GuidelineHodgkin lymphomaGuideline NCCN 2026: Relapse after transplant or transplant-ineligible
Pembrolizumab (KEYNOTE-204) or nivolumab; brentuximab vedotin if not yet given; BV + nivolumab; allogeneic transplant for fit patients after response; CD30 CAR-T in trials; palliative radiotherapy or bendamustine. (NCCN Category 1 (pembrolizumab, nivolumab, brentuximab))
- 2026GuidelineHodgkin lymphomaGuideline NCCN Hodgkin Lymphoma 2026: Early stage, favourable (I-II)
ABVD × 2 + involved-site radiotherapy 20 Gy (HD10), or PET-adapted omission of radiotherapy after 3 cycles if PET-negative (RAPID, HD16) accepting ~5% lower PFS; AHOD2131 tests BV-nivo. (NCCN Category 1 (ABVD × 2 + ISRT 20 Gy or PET-adapted chemotherapy alone))
- 2026MilestoneSWOG S1826Nivolumab-AVD approved by FDA (20 March) for ages 12+; HD21 5-year data confirm BrECADD
A milestone in how this cancer is treated.
- 2026MilestoneNivolumabNivolumab-AVD approved first line
A milestone in how this cancer is treated.
2024 · 2
2023 · 2
November 2022 · 1
2022 · 1
2021 · 2
2020 · 2
March 2018 · 1
2018 · 3
- 2018ApprovalBrentuximab vedotinBrentuximab vedotin approved in US
First-line stage III/IV Hodgkin lymphoma with AVD
- 2018ApprovalSintilimabSintilimab approved in China
Relapsed or refractory classical Hodgkin lymphoma after two or more lines
- 2018MilestoneECHELON-1ECHELON-1: BV-AVD approved frontline; radiotherapy omission trials (RAPID, HD16/17) report
A milestone in how this cancer is treated.
2017 · 2
2016 · 4
- 2016Trial resultCheckMate 205CheckMate 205 reported
ORR 69%.
- 2016Trial resultChildhood Cancer Survivor Study (CCSS)Childhood Cancer Survivor Study (CCSS) reported
15-year all-cause mortality among five-year survivors fell from 12.
- 2016Trial resultRATHLRATHL reported
3-year PFS 85.
- 2016MilestoneRATHLRATHL: bleomycin dropped after negative interim PET; nivolumab approved for relapse (CheckMate 205)
A milestone in how this cancer is treated.
August 2015 · 1
2015 · 2
2014 · 1
2013 · 1
August 2011 · 1
2011 · 3
- 2011ApprovalBrentuximab vedotinBrentuximab vedotin approved in US
Relapsed Hodgkin lymphoma and systemic ALCL
- 2011MilestoneBrentuximab vedotinBrentuximab vedotin approved
A milestone in how this cancer is treated.
- 2011MilestoneBrentuximab vedotinBrentuximab vedotin approved for relapsed disease; CD30 validated as an ADC target
A milestone in how this cancer is treated.